Actualités et vidéos - AMGEN INC.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024 PR Newswire THOUSAND OAKS, Calif., March 9, 2024 SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif. , March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the...

FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer PR Newswire THOUSAND OAKS, Calif., Dec. 13, 2023 Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC 1 If Approved, Tarlatamab Would be the First BiTE ® Therapy for a Major Solid Tumor FDA Target Action Date is June 12, 2024 THOUSAND OAKS, Calif. , Dec. 13, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration...

PostEra annonce une collaboration de recherche avec Amgen pour découvrir des petites molécules thérapeutiques à l'aide de l'intelligence artificielle PR Newswire BOSTON, 17 novembre 2023 BOSTON , 17 novembre 2023 /PRNewswire/ -- PostEra , société de biotechnologie spécialisée dans l'intelligence artificielle pour la découverte préclinique de médicaments, a annoncé aujourd'hui une collaboration multi-cibles avec Amgen, société de biotechnologie de premier plan. Cette collaboration...

PostEra anuncia una colaboración de investigación con Amgen PR Newswire BOSTON, 16 de noviembre de 2023 - PostEra anuncia una colaboración de investigación con Amgen para descubrir terapias de moléculas pequeñas utilizando inteligencia artificial BOSTON , 16 de noviembre de 2023 /PRNewswire/ -- PostEra , una empresa de biotecnología especializada en inteligencia artificial para el descubrimiento de fármacos preclínicos, anunció hoy una colaboración multiobjetivo con Amgen, una empresa...

PostEra gibt Forschungszusammenarbeit mit Amgen zur Entdeckung kleinmolekularer Therapeutika mittels künstlicher Intelligenz bekannt PR Newswire BOSTON, 16. November 2023 BOSTON , 16. November 2023 /PRNewswire/ -- PostEra , ein Biotechnologieunternehmen, das sich auf künstliche Intelligenz für die präklinische Arzneimittelforschung spezialisiert hat, gab heute eine Multi-Target-Zusammenarbeit mit Amgen, einem führenden Biotechnologieunternehmen, bekannt. Die Zusammenarbeit wird die...

PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence PR Newswire BOSTON, Nov. 16, 2023 BOSTON , Nov. 16, 2023 /PRNewswire/ -- PostEra , a biotechnology company specializing in artificial intelligence for preclinical drug discovery, today announced a multi-target collaboration with Amgen, a leading biotechnology company. The collaboration will leverage PostEra's AI platform, Proton , a pioneering innovation in generative...

AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023 PR Newswire THOUSAND OAKS, Calif., Nov. 7, 2023 FOREMOST Study Finds Oral Otezla ® (apremilast) Significantly Improved Disease Control vs. Placebo THOUSAND OAKS, Calif. , Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla ® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study...

AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023 PR Newswire THOUSAND OAKS, Calif., Oct. 19, 2023 THOUSAND OAKS, Calif. , Oct. 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday , Oct. 24, 2023 following the presentation of new data from Amgen's innovative oncology portfolio including AMG 193 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 and data from...

AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023 PR Newswire THOUSAND OAKS, Calif., Oct. 16, 2023 Results From Phase 2 DeLLphi-301 Trial Highlight Potential of Tarlatamab, First BiTE in Patients With Previously Treated SCLC Pivotal Phase 3 CodeBreaK 300 Study Data Support LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) Combination in KRAS G12C-Mutated mCRC Early-Stage Results for AMG 509 (xaluritamig) Illustrate Expanding Potential of Amgen's T-Cell Engagers...

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC PR Newswire THOUSAND OAKS, Calif., Sept. 10, 2023 In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65% THOUSAND OAKS, Calif. , Sept. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS ® (sotorasib) with carboplatin and...

AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Aug. 31, 2023 THOUSAND OAKS, Calif. , Aug. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday , Sept. 6, 2023. Amgen will also present at the Citi Global Healthcare Conference at 1:00 p.m. ET on Thursday , Sept. 7, 2023. Peter H. Griffith , executive vice president and chief...

IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 2, 2023 -­ First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored Phase 1/2 clinical trial ­- Global clinical trial will evaluate IDE397 and AMG 193 combination as potential first-in-class synthetic lethality...

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. (“Amgen”) (NASDAQ: AMGN) breached their fiduciary duties to Amgen and its shareholders. If you are an Amgen shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982, or [email protected] . Scott+Scott is investigating whether members of Amgen’s...

MOORE KUEHN ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM PR Newswire NEW YORK, July 14, 2023 NEW YORK , July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: Amgen Inc. (NASDAQ: AMGN ) ** Please only contact if shares purchased before July 29, 2020 The investigation involves allegations that: (i) the U.S. government claimed Amgen owed more than $3 billion in back taxes for tax years 2010,...

FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PR Newswire THOUSAND OAKS, Calif., June 21, 2023 Conversion From Accelerated to Full Approval Reinforces BLINCYTO as Standard of Care for Patients With Minimal Residual Disease at Baseline After Remission THOUSAND OAKS, Calif. , June 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved...

AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., June 9, 2023 THOUSAND OAKS, Calif. , June 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44 th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday , June 14, 2023. Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be...

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi PR Newswire BRIDGEWATER, N.J., May 18, 2023 Decision unanimously affirms the United States Federal Circuit Court's opinion that Amgen's asserted U.S. PCSK9 patent claims are invalid BRIDGEWATER, N.J. , May 18, 2023 /PRNewswire/ -- Sanofi (NASDAQ: SNY) is pleased with the United States Supreme Court's ruling in Amgen v. Sanofi et. al. The decision...

Horizon Therapeutics plc (Nasdaq: HZNP) today issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company: “This acquisition has the potential to accelerate the availability of important rare disease medicines to more patients worldwide. The FTC’s complaint impacts patients and is rooted in a theory about potential future “bundled” contracts with payors and not competitive overlap concerns. Horizon does not and has no...

AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS PR Newswire THOUSAND OAKS, Calif., May 16, 2023 THOUSAND OAKS, Calif. , May 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc: "Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring...

AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023 PR Newswire NEW YORK, May 12, 2023 NEW YORK , May 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/amgen-inc-lawsuit-submission-form/?id=39264&from=4 This lawsuit is on behalf of all...